Primary Sjögren’s Syndrome Accompanied by Clinical Features of TAFRO Syndrome

Table 1

Laboratory findings of the study patient on admission.

WBC (μL)	8,900
Neutrophils (%)	78.5
Eosinophils (%)	0.5
Monocytes (%)	5.5
Lymphocytes (%)	9.5
RBC (10^6/μL)	3.94
Hb (g/dL)	12.6
Hct (%)	37.5
PLT (10^3/μL)	27
TP (g/dL)	6.5
Alb (g/dL)	3.0
TB (mg/dL)	0.6
AST (U/L)	18
ALT (U/L)	13
LD (U/L)	175
ALP (U/L)	211
γ-GTP (U/L)	44
BUN (mg/dL)	9.3
Creatinine (mg/dL)	0.89
Na (mEq/L)	143
K (mEq/L)	4.3
Cl (mEq/L)	109
CRP (mg/dL)	1.26
CEA (ng/mL)	<0.5
CA19-9 (ng/mL)	<2.0
CA125 (U/mL)	77.3
sIL-2R (U/mL)	745
IgG (mg/dL)	1,643
IgG4 (mg/dL)	38
IgA (mg/dL)	355
IgM (mg/dL)	90
CH50 (U/mL)	60
C3 (mg/dL)	113
C4 (mg/dL)	46.3
RF (IU/mL)	133
ANA (fold)	320
Homogenous (fold)	320
Cytoplasmic	＋
Anti-ds-DNA IgG antibody (IU/mL)	8.3
Anti-Ro/SS-A antibody (fold)	32
Anti-Lo/SS-B antibody (fold)	1
PA-IgG (ng/10^7)	195
Human herpesvirus 8 DNA	−
IL-6 (pg/mL)	3.01
VEGF (pg/mL)	42.1
<Urinalysis>
Protein	±
Sugar	−
Blood	−

WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; Hct, hematocrit; PLT, platelet; TP, total protein; Alb, albumin; TB, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LD, lactic dehydrogenase; ALP, alkaline phosphatase; γ-GTP, γ-glutamyl transpeptidase; BUN, blood urea nitrogen; Na, sodium; K, potassium; Cl, chloride; CRP, C-reactive protein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA125, cancer antigen 125; sIL-2R, soluble interleukin-2 receptor; IgG, immunoglobulin G; IgG4, immunoglobulin G4; IgA, immunoglobulin A; IgM, immunoglobulin M; CH50, 50% hemolytic complement activity; C3, third component of complement; C4, fourth component of complement; RF, rheumatoid factor; ANA, antinuclear antibody; PA-IgG, platelet-associated immunoglobulin G; IL-6, interleukin-6; VEGF, vascular endothelial growth factor.